175 related articles for article (PubMed ID: 19917361)
1. Anti-HLA antibody profile of Turkish patients with end-stage renal disease.
Karahan GE; Seyhun Y; Oguz F; Kekik C; Onal E; Caliskan Y; Bakkaloglu H; Yazici H; Turkmen A; Aydin AE; Sever MS; Eldegez U; Carin MN
Transplant Proc; 2009 Nov; 41(9):3651-4. PubMed ID: 19917361
[TBL] [Abstract][Full Text] [Related]
2. Detection and analysis of HLA class I and class II specific alloantibodies in the sera of dialysis recipients waiting for a renal retransplantation.
Barocci S; Valente U; Nocera A
Clin Transplant; 2007; 21(1):47-56. PubMed ID: 17302591
[TBL] [Abstract][Full Text] [Related]
3. Association of HLA phenotypes of end-stage renal disease patients preparing for first transplantation with anti-HLA antibody status.
Karahan GE; Kekik C; Oguz FS; Onal AE; Bakkaloğlu H; Calişkan YK; Yazici H; Turkmen A; Aydin AE; Sever MS; Eldegez U; Carin MN
Ren Fail; 2010 Jan; 32(3):380-3. PubMed ID: 20370456
[TBL] [Abstract][Full Text] [Related]
4. Panel reactive antibody positivity and associated HLA antibodies in Turkish renal transplant candidates.
Ozdemir FN; Sezer S; Akcay A; Arat Z; Turan M; Gulmus S; Kulah E; Haberal M
Transpl Immunol; 2004 Jan; 12(2):185-8. PubMed ID: 14967317
[TBL] [Abstract][Full Text] [Related]
5. [Anti-HLA antibodies in nephropathic patients].
Argiolas M; Piredda GB; Piras P; Corpino AM; Bajorek M; Todde P
G Ital Nefrol; 2003; 20(4):388-92. PubMed ID: 14523900
[TBL] [Abstract][Full Text] [Related]
6. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
[TBL] [Abstract][Full Text] [Related]
7. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
Lee PC; Ozawa M
Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
[TBL] [Abstract][Full Text] [Related]
8. Aortic valve allograft structural deterioration is associated with a subset of antibodies to human leukocyte antigens.
Dignan R; O'Brien M; Hogan P; Thornton A; Fowler K; Byrne D; Stephens F; Harrocks S
J Heart Valve Dis; 2003 May; 12(3):382-90; discussion 390-1. PubMed ID: 12803340
[TBL] [Abstract][Full Text] [Related]
9. Good kidney transplant outcome in recipients with presensitization against HLA class II but not HLA class I.
Süsal C; Opelz G
Hum Immunol; 2004 Aug; 65(8):810-6. PubMed ID: 15336782
[TBL] [Abstract][Full Text] [Related]
10. Detection of donor-specific anti-HLA class I and II antibodies using antibody monitoring system.
Yang CW; Oh EJ; Lee SB; Moon IS; Kim DG; Choi BS; Park SC; Choi YJ; Park YJ; Han K
Transplant Proc; 2006 Nov; 38(9):2803-6. PubMed ID: 17112834
[TBL] [Abstract][Full Text] [Related]
11. Impact of HLA on the underlying primary diseases in Turkish patients with end-stage renal disease.
Karahan GE; Seyhun Y; Oguz FS; Kekik C; Onal AE; Yazici H; Turkmen A; Aydin AE; Sever MS; Eldegez U; Carin MN
Ren Fail; 2009; 31(1):44-9. PubMed ID: 19142809
[TBL] [Abstract][Full Text] [Related]
12. Post transplant development of MICA and anti-HLA antibodies is associated with acute rejection episodes and renal allograft loss.
Panigrahi A; Gupta N; Siddiqui JA; Margoob A; Bhowmik D; Guleria S; Mehra NK
Hum Immunol; 2007 May; 68(5):362-7. PubMed ID: 17462503
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-converting enzyme genotype is a predictive factor in the peak panel-reactive antibody response.
Akçay A; Ozdemir FN; Ataç FB; Sezer S; Verdi H; Arat Z; Haberal M
Transplant Proc; 2004; 36(1):35-7. PubMed ID: 15013293
[TBL] [Abstract][Full Text] [Related]
14. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome.
Worthington JE; Martin S; Al-Husseini DM; Dyer PA; Johnson RW
Transplantation; 2003 Apr; 75(7):1034-40. PubMed ID: 12698094
[TBL] [Abstract][Full Text] [Related]
15. Identification of the antibodies involved in B-cell crossmatch positivity in renal transplantation.
Le Bas-Bernardet S; Hourmant M; Valentin N; Paitier C; Giral-Classe M; Curry S; Follea G; Soulillou JP; Bignon JD
Transplantation; 2003 Feb; 75(4):477-82. PubMed ID: 12605113
[TBL] [Abstract][Full Text] [Related]
16. Human leucocyte antigens: their association with end-stage renal disease in Saudi patients awaiting transplantation.
Almogren A; Shakoor Z; Hamam KD
Br J Biomed Sci; 2012; 69(4):159-63. PubMed ID: 23304791
[TBL] [Abstract][Full Text] [Related]
17. [Expression of major histocompatibility complex class I-related chain A antibody in patients with end-stage renal disease and its clinical implications].
Xiao LL; Luo M; Yu LX; Zhu W
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Nov; 28(11):1999-2001. PubMed ID: 19033113
[TBL] [Abstract][Full Text] [Related]
18. Risk factors of sensitization to human leukocyte antigen in end-stage renal disease patients.
Hung SY; Lin TM; Chang MY; Wang HH; Lee YC; Ho LC; Chen YT; Hung CM; Liou HH
Hum Immunol; 2014 Jun; 75(6):531-5. PubMed ID: 24607727
[TBL] [Abstract][Full Text] [Related]
19. Presensitized kidney graft recipients with HLA class I and II antibodies are at increased risk for graft failure: a Collaborative Transplant Study report.
Süsal C; Döhler B; Opelz G
Hum Immunol; 2009 Aug; 70(8):569-73. PubMed ID: 19375472
[TBL] [Abstract][Full Text] [Related]
20. Anti-HLA class II antibodies in kidney retransplant patients.
Arnold ML; Pei R; Spriewald B; Wassmuth R
Tissue Antigens; 2005 Apr; 65(4):370-8. PubMed ID: 15787721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
